News & Information
 

Intralytix Receives a Phase I U.S. Army grant supporting the development of a phage-based product for treating wounds infected with Acinetobacter baumannii.

PRESS RELEASE - 09/11/2009

Baltimore, Maryland, U.S.A. September 11, 2009. Intralytix, Inc. announced today that it has received a U.S. Army Phase I STTR grant supporting the development of a phage-based product for treating wounds infected with Acinetobacter baumannii.

"Infected wounds are one of the most significant challenges in modern medicine especially in view of the rapid emergence of multiantibiotic-resistant bacteria,"? stated Alexander Sulakvelidze, Intralytix's Vice-President for Research and Development and Chief Scientist of the Company, and Principal Investigator of the STTR grant. He added: "Wounds from high-velocity gunshot, shrapnel and blunt trauma injuries, as well as burns inflicted during combat operations, frequently get infected with bacteria. This complicates their healing, often necessitates repeated surgical interventions, and may lead to amputation of a limb, or even death, of the injured soldier. A. baumannii is one of the major culprits in that regard, and we are pleased to be able to initiate studies using our bacteriophage technology to develop safe and effective tools for managing A. baumannii wound infections."

"This grant increases the breadth of Intralytix's portfolio of phage-based products, and it demonstrates the U.S. Army's confidence in Intralytix's leadership in developing bacteriophage-based preparations for military and civilian populations," noted the company's CEO, John Woloszyn. He also stated: "If the studies during our Phase I project are successful as we fully anticipate they will provide a strong basis for moving forward with Phase II grant support from the Army, which will play a major role in bringing this exciting technology and product closer to the marketplace. It will also make this much-needed approach available where it is most urgently needed, to help civilians and soldiers in various combat zones, including Afghanistan and Iraq. In that regard, a high incidence of A. baumannii infections among our troops in Iraq prompted its nickname "Iraqibacter." Mr. Woloszyn also noted that Army grants have previously supported the development of other phage-based products, including phage-based food additives that protect food from E. coli O157:H7, Salmonella and Shigella. Intralytix, Inc is a biotechnology company focused on using its core bacteriophage/phage technology platform to improve human health through the development and commercialization of innovative products for food safety and human therapeutics.


For more information, contact John Woloszyn (410-625-0300 / jwoloszyn@intralytix.com) or Dr. Alexander Sulakvelidze (410-625-2533 / asulakvelidze@intralytix.com).

Sep 11, 2009

Back to news archive



Technology

Food Safety

Environmental Sanitation

Veterinary Applications

Human Therapeutics

Probiotics